Gilead Sciences stock price target raised to $131 from $117 at Mizuho

Mizuho raised its price target on Gilead Sciences (GILD) to $131 from $117, maintaining an Outperform rating, primarily due to increased peak sales estimates for its multiple myeloma treatment anito-cel (now $6 billion) and the integration of Yeztugo (projected $8 billion peak sales) into its HIV base business. This upgrade, coupled with Gilead's strong Q2 performance and raised full-year revenue guidance, reflects broader analyst confidence in the company's pipeline and strategic execution, particularly within its historically robust HIV segment.

Analysis

Gilead Sciences (GILD) is experiencing a wave of positive analyst sentiment, spearheaded by Mizuho's price target increase to $131 from $117. This upgrade is substantively driven by significantly raised peak sales forecasts for two key assets: the multiple myeloma treatment anito-cel, now projected at approximately $6 billion versus $3.4 billion previously, and the newly approved HIV therapy Yeztugo, estimated at $8 billion, well above the $5 billion consensus. This bullish outlook is further corroborated by strong recent Q2 results, which featured $7.1 billion in total sales, a $1.97 EPS, and a $500 million increase to the full-year revenue guidance, excluding Veklury. The market has reacted in kind, with other major firms like BofA Securities ($140 target) and Morgan Stanley ($143 target) also raising their estimates. This positive momentum is reflected in the stock's 66% return over the past year and its position near a 52-week high. While the consensus is overwhelmingly positive, evidenced by eight upward earnings revisions, RBC Capital's more modest $98 target provides a note of caution, citing some underperforming areas alongside key franchise strengths.

Key Decisions for Investors

• Given the broad analyst consensus and upwardly revised peak sales estimates for key pipeline assets, investors could view the fundamental outlook for Gilead as increasingly positive.
• Monitor the commercial execution of the recently approved HIV drug Yeztugo and the clinical progress of anito-cel, as their multi-billion dollar sales projections are now central to the stock's revised valuation and future growth narrative.
• Considering the stock's significant 66% appreciation over the last year, investors should be mindful of the elevated valuation and acknowledge the more conservative price targets, such as RBC's, as a potential risk factor against the prevailing bullish sentiment.